Oslo, 18 March 2020 – Navamedic ASA (OSE: NAVA), today provides an operational update with regards to covid-19. The company reports normal overall demand for its products and steady delivery from suppliers.
“The covid-19 situation is serious and Navamedic is contributing to the national health authorities’ and healthcare professionals’ work to limit infections by running our operations according to current provisions and recommendations. We are taking the necessary measures to safeguard our employees, customers, suppliers and business contacts, and to ensure normal supply and delivery of products,” says Kathrine Gamborg Andreassen, CEO of Navamedic.
Navamedic proactively manages its value chain closely. Suppliers report that they have been building up stock to prepare for the covid-19 situation, resulting in no products currently out of stock.
“We are also experiencing normal overall demand for our products. Product categories such as cardiology and medical nutrition include products which are essential to end-customers in their everyday life. Navamedic plays a vital role in securing stable delivery of these products, and other products across our portfolio,” says Gamborg Andreassen.
Navamedic will continue monitoring the market situation and its operations closely.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com